Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview

JCO Precis Oncol. 2023 Sep:7:e2300299. doi: 10.1200/PO.23.00299.

Abstract

Complete response to Trametinib in a heavily-pretreated sarcoma: RAF1 as a predictor of MEKi Response

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Fibrosarcoma* / drug therapy
  • Fibrosarcoma* / genetics
  • Humans
  • Mitogen-Activated Protein Kinase Kinases
  • Proto-Oncogene Proteins c-raf*

Substances

  • Proto-Oncogene Proteins c-raf
  • Mitogen-Activated Protein Kinase Kinases